Why cancer is easily transferred to the liver?

Share This Post

A Duke University study has shown that metastatic cancer cells can regulate the metabolic function to reproduce in new organs. Cells derived from colorectal cancer have changed their metabolic habits, making full use of fructose in the liver as much as possible. Once the cancer has spread to different parts of the body, the cancer becomes more deadly, but the treatment does not consider the location of its metastasis and is treated according to the original site. From a genetic point of view, colon cancer is colon cancer, no matter where it is transferred. But this does not mean that it cannot respond to the new environment. This response may not be genetic, but metabolic. When cancer cells enter the liver, they are like a child in a candy store, using this abundant new energy to create more cancer cells. In order to feed on fructose, cancer cells need to produce more enzymes that can break down fructose, called ALDOB. Once cancer cells find out how to turn fructose back on, cancer cells will lose control and proliferate. In addition to providing reasons for how cancer proliferates after metastasis, this discovery can also lead to new therapies for metastatic cells. For example, avoiding the use of fructose by eating natural non-processed foods and providing drugs that block the metabolism of fructose may prevent cancer from spreading from other organs to the liver. Since pharmaceutical companies have recently developed new drugs for fructose metabolism to treat metabolic diseases, this crossover therapy may not be far away. Doctors can usually remove the primary tumor. But understanding the causes of cancer metastasis and how to adapt to a new home may provide us with a new weapon against cancer.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

After amazing growth of CAR T-Cell therapy what's next
CAR T-Cell therapy

After amazing growth of CAR T-Cell therapy: what’s next?

CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient’s T-cells to attack cancer cells, demonstrating remarkable success in hematologic cancers. Advances in genetic engineering, regulatory support, and investment are driving further expansion. Researchers are now tackling the challenges of applying this therapy to solid tumors, aiming to enhance efficacy and accessibility, marking a new era in personalized cancer therapy and immunotherapy.

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Cancer

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy